Glaukos Announces Third Quarter 2026 Financial Results
Business Wire•28/10/2026•16:05 ET
0
Key Highlights
- ➤Q3 net sales $211.0 million, up 58% year-over-year
- ➤Corneal Health sales $59.0 million, up 154% year-over-year
- ➤Non-GAAP diluted EPS $0.47 versus ($0.16) loss
- ➤2026 sales guidance raised to $775 million-$785 million
- ➤Preliminary 2027 sales guidance introduced at $1 billion
Expert Statements
Thomas Burns, Chairman and chief executive officer of Glaukos
“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa.”
Thomas Burns, Chairman and chief executive officer of Glaukos
“We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include:
* Record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis.
Get started
Create a free account to read the full story.